Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Minoru Kato

Showing results (161-170 of 173) with videos related to

Pageof 18
Sort By:
International Journal of Urology : Official Journal of the Japanese Urological Association|September 21, 2021
Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumabMinoru Kato, Takashi Kobayashi, Yoshiyuki Matsui, et al.
Urologic Oncology|August 29, 2021
Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinomaRikiya Taoka, Takashi Kobayashi, Yu Hidaka, et al.
BJU International|June 10, 2021
Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysisMizuki Kobayashi, Shintaro Narita, Yoshiyuki Matsui, et al.
Scientific Reports|January 3, 2025
Effectiveness of tacrolimus therapy in refractory ulcerative colitis compared to infliximab with propensity score matchingTakeo Yoshihara, Takahiro Amano, Shinichiro Shinzaki, et al.
Scientific Reports|November 29, 2024
Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel diseaseTakahiro Amano, Takeo Yoshihara, Shinichiro Shinzaki, et al.
BJU International|February 12, 2024
Prognostic impact of histological discordance between transurethral resection and radical cystectomyAyumu Matsuda, Rikiya Taoka, Jun Miki, et al.
International Journal of Clinical Oncology|May 10, 2025
Impact of lymph-node dissection during radical cystectomy for non-muscle-invasive bladder cancer: Japanese multicenter retrospective studyTomokazu Sazuka, Rikiya Taoka, Jun Miki, et al.
International Journal of Clinical Oncology|July 21, 2025
Efficacy of cisplatin-based neoadjuvant chemotherapy and risk factors for residual extravesical disease in muscle-invasive bladder cancer: insights from a nationwide cohortRyoichi Saito, Rikiya Taoka, Jun Miki, et al.
Cancer Medicine|April 30, 2025
Effects of the Number of Neoadjuvant Cycles and Addition of Adjuvant Chemotherapy on the Prognosis of Muscle-Invasive Bladder Cancer Treated With Radical CystectomyShingo Hatakeyama, Rikiya Taoka, Jun Miki, et al.
Japanese Journal of Clinical Oncology|January 16, 2026
Age-stratified outcomes of radical cystectomy for muscle-invasive bladder cancer: a nationwide multicenter study of 1867 patients in JapanTaketo Kawai, Jun Miki, Rikiya Taoka, et al.
Pageof 18

Showing results (161-170 of 173) with videos related to

Sort By:
Pageof 18
International Journal of Urology : Official Journal of the Japanese Urological Association|September 21, 2021
Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumabMinoru Kato, Takashi Kobayashi, Yoshiyuki Matsui, et al.
Urologic Oncology|August 29, 2021
Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinomaRikiya Taoka, Takashi Kobayashi, Yu Hidaka, et al.
BJU International|June 10, 2021
Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysisMizuki Kobayashi, Shintaro Narita, Yoshiyuki Matsui, et al.
Scientific Reports|January 3, 2025
Effectiveness of tacrolimus therapy in refractory ulcerative colitis compared to infliximab with propensity score matchingTakeo Yoshihara, Takahiro Amano, Shinichiro Shinzaki, et al.
Scientific Reports|November 29, 2024
Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel diseaseTakahiro Amano, Takeo Yoshihara, Shinichiro Shinzaki, et al.
BJU International|February 12, 2024
Prognostic impact of histological discordance between transurethral resection and radical cystectomyAyumu Matsuda, Rikiya Taoka, Jun Miki, et al.
International Journal of Clinical Oncology|May 10, 2025
Impact of lymph-node dissection during radical cystectomy for non-muscle-invasive bladder cancer: Japanese multicenter retrospective studyTomokazu Sazuka, Rikiya Taoka, Jun Miki, et al.
International Journal of Clinical Oncology|July 21, 2025
Efficacy of cisplatin-based neoadjuvant chemotherapy and risk factors for residual extravesical disease in muscle-invasive bladder cancer: insights from a nationwide cohortRyoichi Saito, Rikiya Taoka, Jun Miki, et al.
Cancer Medicine|April 30, 2025
Effects of the Number of Neoadjuvant Cycles and Addition of Adjuvant Chemotherapy on the Prognosis of Muscle-Invasive Bladder Cancer Treated With Radical CystectomyShingo Hatakeyama, Rikiya Taoka, Jun Miki, et al.
Japanese Journal of Clinical Oncology|January 16, 2026
Age-stratified outcomes of radical cystectomy for muscle-invasive bladder cancer: a nationwide multicenter study of 1867 patients in JapanTaketo Kawai, Jun Miki, Rikiya Taoka, et al.
Pageof 18